Pipeline
Phase 4 data presents early patient-reported outcomes of MIEBO
Study finds symptom relief achieved as early as 5 to 60 minutes on day 1 of dosing—with significant reduction in overall severity after 14 days.
Research
KALAHARI phase 3 extension trial data published on MIEBO
Long-term safety and efficacy results on the prescription eye drop published in Cornea.Products
Bausch + Lomb launches MIEBO in the US
Preservative-free eye drop is the first and only approved DED treatment that directly targets tear evaporation.
Products
Bausch + Lomb and Novaliq receive FDA approval for MIEBO to treat DED
Formerly known as NOV03, the ophthalmic solution is now the first and only approved DED treatment directly targeting tear evaporation.
Pipeline
Bausch + Lomb dry eye combo drop advances to phase 3 evaluation
Formulation includes active ingredients of XIIDRA and MIEBO; positive data also reported on a first-in-class drop for targeting ocular pain signaling.
Research
Clinical review calls for upper eyelid imaging in meibomian gland evaluations
Study highlights four key areas where upper eyelid assessment can aid in earlier detection of ocular diseases and systemic conditions.
Products
Scope Health debuts OPTASE cloud-based meibographer and digital solution
Newly-acquired technologies feature a portable device with HD imaging as well as a customizable, HIPAA-compliant cloud server for dry eye clinics.
Products
FDA expands TearCare System indication for MG function improvement
Label update makes the 510(k)-cleared device the first and only for this indication; includes an optional debridement.
Pipeline
Azura gets positive FDA feedback on NDA submission for MGD ointment
Positive pre-NDA meeting for selenium sulfide ointment precedes planned phase 3 data release in Q1 2026 and regulatory submission in H2 2026.
Research
24-month data from SAHARA RCT supports TearCare durability for DED
Third set of findings from the long-term study indicates the FDA-cleared system’s ability to deliver “immediate, powerful, repeatable, and long-lasting” dry eye relief.
Research
SAHARA crossover trial reports significant continued advantages of TearCare for DED
Additional 6-month data supports Sights Sciences’ tech vs Restasis as a primary treatment for addressing the underlying root cause of MGD.
Pipeline
Tarsus announces positive phase 2a topline data on TP-03 for MGD
Results demonstrate potential for TP-03 as a second indication to treat MGD with Demodex mites.
Pipeline
New 6-month data evaluates AZR-MD-001 for MGD
Presented at AAOPT, latest findings follow previous 3-month data evaluating the efficacy of two dosages.
Research
Is thermal pulsation effective for MGD in dry eye?
Investigators assessed the use of the LipiFlow system against conventional therapies.
Research
Sight Sciences reports positive 6-month data from trial on TearCare vs Restasis for dry eye
SAHARA trial meets primary endpoint in support of technology, with detailed results to be presented at AAO 2023.
Research
Study supports reduced dosing for doxycycline alternative in MGD
Oral azithromycin for severe meibomian gland dysfunction cuts treatment time in half.
Pipeline
Bausch + Lomb, Novaliq release second phase 3 data for NOV03
Results from MOJAVE study support potential for treating DED associated with MGD.
Research
TearRestore releases positive topline results from MGD study
Trial tests the effectiveness of TearRestore’s eyelid warming mask tests on symptoms of MGD.
Research
Why MGD and dyslipidemia may go hand-in-hand
Study suggests an MGD diagnosis could indicate the need for screenings.
Archives